Publication | Closed Access
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma
86
Citations
37
References
2015
Year
MedicineLung AdenocarcinomaPathologyPhase Ii StudyBronchial NeoplasmCancer GeneticsOncologyRadiation OncologyLung Cancer
| Year | Citations | |
|---|---|---|
Page 1
Page 1